Zillow, Seagate upgrades among today's top calls on Wall Street » 10:3108/0408/04/20
Z, ZG, STX, MCK, TTWO, NKTX
Check out today's top…
Mizuho starts Nkarta with Buy rating, $34 price target » 07:0608/0408/04/20
Mizuho analyst Salim Syed…
Mizuho analyst Salim Syed initiated coverage of Nkarta with a Buy rating and $34 price target. The analyst believes natural killer cell biology is "naturally much more elegant than T cell biology." NK cells express a wide variety of inhibitory receptors that identify healthy normal cells, and activating receptors that recognize diseased cells, Syed tells investors in a research note. The analyst points out that Nkarta is developing allogeneic engineered NK cell based therapies to treat cancer.
Nkarta initiated with an Outperform at Evercore ISI » 06:4308/0408/04/20
Evercore ISI initiated…
Evercore ISI initiated coverage of Nkarta with an Outperform rating and $55 price target.
Nkarta initiated with a Buy at Stifel » 06:2808/0408/04/20
Stifel analyst Stephen…
Stifel analyst Stephen Willey initiated coverage of Nkarta with a Buy rating and $41 price target. The company's natural killer, or NK, cell engineering platform overcomes the historical challenges associated with ex-vivo NK cell manipulation, said Willey, who sees harnessing NK cells as "the next significant chapter in the generation of engineered cell-based therapies to treat cancer." However, he acknowledges longer-term data will ultimately be needed to discern any meaningful differences in competing platform technologies.
Nkarta initiated with a Buy at Mizuho » 06:1808/0408/04/20
Mizuho analyst Salim Syed…
Mizuho analyst Salim Syed initiated coverage of Nkarta with a Buy rating and $34 price target.
Nkarta initiated with an Outperform at Cowen » 06:1708/0408/04/20
Cowen initiated coverage…
Cowen initiated coverage of Nkarta with an Outperform rating.
|Over a week ago|
Dun & Bradstreet initiated with a Neutral at Citi » 06:3207/2807/28/20
Citi analyst Peter…
Citi analyst Peter Christiansen initiated coverage of Dun & Bradstreet with a Neutral rating and $28 price target. The analyst believes current stock levels are pricing in a "faster turnaround with no major hiccups along away." He expects Dun & Bradstreet's turnaround efforts to "gradually materialize" over the next few years, allowing investors to "wait and see more proof points."
Accolade initiated with an Outperform at Baird » 13:5207/2707/27/20
Baird analyst Matthew…
Baird analyst Matthew Gillmor initiated coverage of Accolade with an Outperform rating and $40 price target. The company, whose tech-enabled platform integrates health/benefit offerings and drives "differentiated results for employer clients," is in the early stages of redefining the healthcare member navigation experience, Gillmor contends. He sees Accolade having a large market opportunity and "highly visible" path to greater than 20% annual growth.
Fly Intel: Top five analyst initiations » 10:1707/2707/27/20
IMTX, STSA, OSK, LMND, ACCD
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Immatics (IMTX) initiated with an Outperform at SVB Leerink. 2. Satsuma Pharmaceuticals (STSA) initiated with a Buy at H.C. Wainwright. 3. Oshkosh (OSK) initiated with an Outperform at Raymond James. 4. Lemonade (LMND) was initiated with an Outperform at JMP Securities, a Market Perform at William Blair, a Perform at Oppenheimer, an Equal Weight at Barclays and Morgan Stanley, and a Sell at Goldman Sachs. 5. Accolade (ACCD) initiated with a Buy at Goldman Sachs and BofA, an Overweight at Morgan Stanley and Piper Sandler, a Market Perform at SVB Leerinkm, and a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Accolade initiated with a Market Perform at SVB Leerink » 09:3107/2707/27/20
As previously reported,…
As previously reported, SVB Leerink analyst Stephanie Davis initiated coverage of Accolade with a Market Perform rating and $34 price target. The analyst notes that Accolade operates as a healthcare navigation and benefits management platform, helping client members navigate and optimize their care journey. Davis believes the growing cohort of employee-benefits facing names within the health tech universe solidifies the long-term need for Accolade's care navigation platform, although she acknowledges the growth trajectory is not without near-term risk due to pandemic headwinds. While the analyst fundamentally likes the story, with shares rallying nearly 50% since coming public she sees only modest upside from current levels.